Eisai

"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan

Retrieved on: 
Monday, September 25, 2023
Amyloid-related imaging abnormalities, PMID, Outline, Clinical trial, Marketing, The New England Journal of Medicine, Deficit spending, Pathology, Ministry of Health, Labour and Welfare, Research, Brain, Siderosis, History, MCI, The Different Forms of Flowers on Plants of the Same Species, Clarity, Ministry, ARIA, Dementia, HIV disease progression rates, Patient, Immunoglobulin G, Superficial siderosis, PLOS One, Co-promotion, Ministry of Health (Kuwait), Therapy, Headache, Neurotoxicity, Disease, ADCS, Pharmaceutical industry, Alzheimer's disease, Biogen, Amyloid beta, Health, Eisai

Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.

Key Points: 
  • Japan is the second country to grant approval, following the traditional approval in the U.S. in July 2023.
  • In the Clarity AD clinical trial, treatment with LEQEMBI reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.
  • "Today LEQEMBI received approval, making it the first approved anti-amyloid Alzheimer's disease treatment shown to reduce the rate of disease progression and to slow cognitive impairment in the early and mild dementia stages of the disease in Japan.
  • In Japan, Eisai and Biogen Japan will co-promote LEQEMBI, with Eisai distributing the product as the Marketing Authorization Holder.

Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21

Retrieved on: 
Thursday, September 21, 2023
Learning, Life Goes On, Anxiety, Ageing, Timeslip, Eisai, Dementia, Family, Disease, Residential care

TOKYO, Sept 21, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today on World Alzheimer's Day, that it has released a dementia awareness video, "Life Goes On 2023: Two Memories, One Story", on its dementia information website "Sodan.e-65" and YouTube, which are intended to deepen the understanding of dementia.

Key Points: 
  • TOKYO, Sept 21, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today on World Alzheimer's Day, that it has released a dementia awareness video, "Life Goes On 2023: Two Memories, One Story", on its dementia information website "Sodan.e-65" and YouTube, which are intended to deepen the understanding of dementia.
  • With the rapidly aging population, it is predicted that by 2025, one in five people over the age of 65 in Japan will have dementia,(1) and dementia is now something that is familiar to everyone.
  • A story of a couple and their family accepting life with dementia and moving forward.
  • Eisai will continue to contribute to realize a Dementia Inclusive Society where no one is left behind through creating social impact by building a dementia ecosystem via collaboration with local governments and other industries.

Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer

Retrieved on: 
Friday, September 22, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, Docetaxel, Senior, Hepatocellular carcinoma, RCC, Lenvatinib, Pembrolizumab, OS, MRK, Lung cancer, Head, Multimedia, NSCLC, Biomarker, PFS, Merck & Co., LEAP, Cancer, Patient, EGFR, Anaplastic lymphoma kinase, ROS1, Esophageal cancer, Stomach, Pemetrexed, NYSE, ORR, ALK, Pharmaceutical industry, Medical imaging, EU, Eisai, Merck

At the study’s final analysis, there was not an improvement in OS for patients treated with KEYTRUDA plus LENVIMA with chemotherapy compared to KEYTRUDA with chemotherapy.

Key Points: 
  • At the study’s final analysis, there was not an improvement in OS for patients treated with KEYTRUDA plus LENVIMA with chemotherapy compared to KEYTRUDA with chemotherapy.
  • Earlier interim analyses did not demonstrate a statistically significant improvement in PFS or objective response rate (ORR), a key secondary endpoint.
  • At the final analysis of the study, there was not an improvement in OS for patients who received KEYTRUDA plus LENVIMA compared to docetaxel.
  • Results from the LEAP-006 and LEAP-008 trials do not affect the current approved indications for the KEYTRUDA plus LENVIMA combination or other ongoing trials from the LEAP clinical program.

Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem

Retrieved on: 
Tuesday, September 12, 2023
Communication, Personal health record, MCI, ADL, Trial of the century, Dementia, Algorithm, PHR, Ecosystem, Caregiver, Disease, Residential care, Eisai, Christian mysticism

TOKYO, Sept 12, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has established a digital business company Theoria technologies Co., Ltd. ("Theoria technologies") which will accelerate the development of a dementia ecosystem.

Key Points: 
  • TOKYO, Sept 12, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has established a digital business company Theoria technologies Co., Ltd. ("Theoria technologies") which will accelerate the development of a dementia ecosystem.
  • Theoria technologies is a wholly owned subsidiary of Eisai.
  • In addition, together with Eisai, Theoria technologies will develop and provide Sasaeru, an application that helps facilitate communication between people with dementia, doctors, and caregivers by recording Activities of Daily Living (ADL) of the people with dementia.
  • Furthermore, Theoria technologies will promote the development of digital services by strengthening collaboration with other companies.

Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD. as Senior Vice President of Clinical Development

Retrieved on: 
Wednesday, September 6, 2023
Prostate Cancer Foundation, Surgical oncology, Royal college, Society, Immunoconjugate, Therapy, Prostate cancer, PSMA, Convergent, Drug, Bayer, Cancer, Radiopharmaceutical, Triplet, Eisai, Surgical Innovation, MD, Patient, Gemini, Weill Cornell Medicine, CFO, Growth, Merrimack Pharmaceuticals, Pharmaceutical industry

These appointments follow the company's recent closing of a $90 million Series A financing round to develop radiopharmaceuticals to treat cancer.

Key Points: 
  • These appointments follow the company's recent closing of a $90 million Series A financing round to develop radiopharmaceuticals to treat cancer.
  • "With our strong financial backing, we are poised to accelerate the clinical development of our lead asset CONV01-a to transform the lives of patients suffering with prostate cancer."
  • Over the past 25 years, Dr. Bander pioneered the development of PSMA-targeted imaging agents and therapeutics, transforming the prostate cancer landscape.
  • Dr. Voliotis is joining Convergent from Zentalis Pharmaceuticals, where he was Senior Vice President & Head of Global Development.

Global Alzheimer's Disease Market 2023-2032: LEQEMBI and Donanemab Reshape Treatment Landscape - ResearchAndMarkets.com

Retrieved on: 
Monday, August 28, 2023
Health, Pharmaceutical, EU4, CMS, Prevalence, Dabigatran, Biogen, Internet, Pathology, Ageing, Conjoint analysis, Hope, NMDA, Dementia, Eli Lilly, Medicare, Eisai, SWOT, Patient, Donanemab, Conjoint, Growth, Epidemiology, Safety, Disease, Pharmaceutical industry, Alzheimer's disease

Alzheimer's disease, a progressive neurodegenerative disorder, is on the rise due to the aging population and increased disease awareness.

Key Points: 
  • Alzheimer's disease, a progressive neurodegenerative disorder, is on the rise due to the aging population and increased disease awareness.
  • While the current treatment focuses on managing symptoms and slowing disease progression, recent breakthroughs in disease-modifying therapies are changing the landscape.
  • This report delves into key highlights, emerging therapies, market trends, and the epidemiology of Alzheimer's disease in the 7MM (United States, EU4, UK, and Japan).
  • The Alzheimer's disease landscape is witnessing transformative changes, driven by breakthrough therapies like LEQEMBI and donanemab.

Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Retrieved on: 
Friday, August 25, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Senior, Hepatocellular carcinoma, Progression-free survival, RCC, Neoplasm, Lenvatinib, Pembrolizumab, Overalls, Survival, OS, MRK, Head, TKI, Multimedia, Research, Lung cancer, Immunotherapy, PFS, Merck & Co., LEAP, Cancer, Patient, Esophageal cancer, HNSCC, Data monitoring committee, Stomach, PD-L1, NYSE, ORR, DMC, Pharmaceutical industry, EU, Eisai, Merck

The primary endpoints of the study were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).

Key Points: 
  • The primary endpoints of the study were overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).
  • View the full release here: https://www.businesswire.com/news/home/20230825671284/en/
    Two planned interim analyses were conducted by an independent Data Monitoring Committee (DMC) over an 11-month period.
  • In the first analysis, KEYTRUDA plus LENVIMA showed a statistically significant improvement in PFS and ORR versus KEYTRUDA plus placebo.
  • The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

Catalyst Pharmaceuticals Announces Multiple Abstracts on FYCOMPA® (Perampanel) from Eisai Co, Ltd., to be Presented at the 35th International Epilepsy Congress

Retrieved on: 
Monday, August 14, 2023
Abstract, Abstract (summary), Availability, Pharmacotherapy, Sleep, Q&A, AMPA, Safety, Catalyst Pharmaceuticals, Perampanel, Ageing, CIII, Doctor of Philosophy, Quality, Combination therapy, Congress, Eisai, MD, Quality of life, IEC, Effectiveness, Digital, Rare, CORAL, Treatment, Pharmaceutical industry, Medical imaging, Medical device, Online shopping, Residential care, Epilepsy, Patient, Catalysis

These are presentations by Eisai Co., Ltd. ("Eisai"), which holds the rights to FYCOMPA in countries and regions outside the U.S.

Key Points: 
  • These are presentations by Eisai Co., Ltd. ("Eisai"), which holds the rights to FYCOMPA in countries and regions outside the U.S.
  • Some abstracts will also be considered for publication in Epilepsia following the IEC.
  • The accepted abstracts and presentations detail the results from clinical and real-world studies, further documenting the uses of perampanel in both focal and generalized epilepsy across a diverse range of patients.
  • “These findings, which are being presented at IEC, further validate and add to the growing body of evidence supporting the benefits of perampanel in the treatment of seizure disorders,” said Gary Ingenito, MD, PhD, Chief Medical and Regulatory Officer of Catalyst.

EISAI INC.'S U.S. HEADQUARTERS EARNS THREE KEY BUILDING CERTIFICATIONS

Retrieved on: 
Thursday, August 17, 2023
Group Policy, Maintenance, Partnership, Emergency, Atmosphere, LEED, Water quality, Carbon dioxide, WELL, Recycling, Carbon, Water supply, Climate change, Biophysical environment, Workplace (Health, Safety and Welfare) Regulations 1992, U.S. Green Building Council, Environment, Policy, Ecosystem, Health, CO2, Safety, Wellness, Green Standard Army, Management, Nursing, Renewable energy, Eisai

NUTLEY, N.J., Aug. 17, 2023 /PRNewswire/ -- Eisai Inc., the United States-based pharmaceutical subsidiary of Eisai Co., Ltd., continues to demonstrate its commitment to contribute to a more sustainable world by achieving three well-known environmental and health and wellness certifications at its U.S. headquarters, the Eisai U.S. hhceco Center, in Nutley, N.J. Eisai earned the prestigious LEED (Leadership in Energy and Environmental Design)®, Fitwel® and WELL Health-Safety Rating™ certifications.

Key Points: 
  • When Eisai began building out the Eisai US hhceco Center in 2020, the company sought to earn important certifications that focused on its commitment to environmental protection and energy efficiency.
  • Eisai's Site Services and cross functional design teams led the effort to ensure essential components required for various certifications – energy usage, water consumption, recycling and air quality – were incorporated into the design of its headquarters.
  • They also embraced initiatives that helped improve the health and wellness of their employees.
  • Fueled by its global commitment to sustainability, Eisai targeted and achieved three major certifications at the Eisai US hhceco Center:
    LEED® certification, created and maintained by the U.S. Green Building Council, rates the design, construction, operation and maintenance of green buildings, homes and neighborhoods to help building owners and operators be environmentally responsible and use resources efficiently.

Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment

Retrieved on: 
Friday, August 4, 2023
Carbon, Government Pension Investment Fund, FTSE Russell, Corporate governance, WIN, Index, Eisai, MSCI, Patient, ESG, Anti-corruption

The FTSE4Good Index Series is a global index series for socially responsible investment.

Key Points: 
  • The FTSE4Good Index Series is a global index series for socially responsible investment.
  • The FTSE4Good Index Series was developed by FTSE Russell to promote investment in companies that meet global environmental, social and governance (ESG) standards.
  • As of the end of June 2023, 1,121 companies worldwide and 250 Japanese companies were included in the FTSE4Good Developed Index Series.
  • Currently, in addition to the MSCI ESG Leaders Indexes, another global ESG investment index, Eisai is also listed in the FTSE Blossom Japan Index, the FTSE Blossom Japan Sector Relative Index, the MSCI Japan ESG Select Leaders Index, the MSCI Japan Empowering Women Index (WIN) and the S&P/JPX Carbon Efficient Index, which are ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).